Top Qs
Timeline
Chat
Perspective
DOB-CR
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
DOB-CR, or DOB/CR, , an acronym of "DOB-conformationally restrained", also known as 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the tetrahydroisoquinoline family.[1][2][3][4] It is a cyclized phenethylamine and a derivative of the psychedelic drugs 2C-B and DOB in which the side chain has been cyclized with the benzene ring to form a tetrahydroisoquinoline (THIQ) ring system.[1][2][4][3]
Remove ads
Pharmacology
The drug shows modest affinity for the serotonin 5-HT2A receptor.[1][3] Its affinity (Ki) for the receptor was 242 to 250 nM, which is about 6-fold lower than that of DOB.[1][3] In contrast to DOB, DOB-CR completely failed to substitute for DOM in rodent drug discrimination tests.[1][2][3][4] In addition, behavioral disruption occurred at higher doses.[1][3] These findings suggest that DOB-CR would lack psychedelic effects in humans.[1][2][3][4] The drug also failed to substitute for dextroamphetamine and MDMA in rodent drug discrimination tests, suggesting lack of stimulant or entactogenic effects as well.[4] However, DOB-CR fully substituted for the structurally related selective α2-adrenergic receptor ligand TDIQ (MDTHIQ or MDA-CR), albeit with about 4-fold lower potency than TDIQ itself.[2][4]
Remove ads
History
DOB-CR was first described in the scientific literature by Richard Glennon and colleagues by 1996.[1][3]
See also
- Substituted tetrahydroisoquinoline
- Cyclized phenethylamine
- DOM-CR
- TDIQ (MDTHIQ or MDA-CR)
- Tetrahydroisoquinoline (THIQ; AMPH-CR)
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads